Abstract
Alzheimer’s disease (AD) is a progressive degenerative disorder of the brain that begins with memory impairment and eventually progresses to dementia, physical impairment, and death. Patients develop various psychiatric and neurological signs during the course of the disease. The prevalence rates of dementia vary significantly in different countries, but range from 2.1 to 10.5%. AD is the most common type of dementia, accounting for 50–60% of all cases, and is described in detail in a special report on AD (Jain 2010).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Bachurin S, Bukatina E, Lermontova N, et al. Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann N Y Acad Sci 2001;939:425–35.
Becker JT, Davis SW, Hayashi KM, et al. Three-dimensional patterns of hippocampal atrophy in mild cognitive impairment. Arch Neurol 2006;63:97–101.
Bennett DA, Schneider JA, Bienias JL, et al. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 2005;64:834–41.
Busse A, Bischkopf J, Riedel-Heller SG, et al. Mild cognitive impairment: prevalence and predictive validity according to current approaches. Acta Neurol Scand 2003;108:71–81.
Capsoni S, Giannotta S, Cattaneo A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc Natl Acad Sci U S A 2002;99:12432–7.
Dodge HH, Zitzelberger T, Oken BS, et al. A randomized placebo-controlled trial of ginkgo biloba for the prevention of cognitive decline. Neurology 2008;70:1809–17.
Donnelly PS, Xiao Z, Wedd AG. Copper and Alzheimer’s disease. Curr Opin Chem Biol 2007;11:128–33.
Eubanks LM, Rogers CJ, Beuscher AE, et al. A molecular link between the active component of marijuana and Alzheimer’s disease pathology. Mol Pharm 2006;3:773–7.
Griffin WS. Perispinal etanercept: potential as an Alzheimer therapeutic. J Neuroinflammation 2008;5:3.
Grigorev VV, Dranyi OA, Bachurin SO. Comparative study of action mechanisms of dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons. Bull Exp Biol Med 2003;136:474–7.
Higgins PJ. The TGF-beta1/upstream stimulatory factor-regulated PAI-1 gene: potential involvement and a therapeutic target in Alzheimer’s disease. J Biomed Biotechnol 2006;2006:15792.
Hoerr R. Treatment effects of EGb 761 and cholinesterase inhibitors – why available studies do not demonstrate superiority of the latter. Phytomedicine 2005;12:598–600.
in t’ Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med 2001;345:1515–21.
Jain KK. An evaluation of memantine in the management of dementia. Expert Opin Investig Drugs 2000;9:1397–406.
Jain KK. Alzheimer Disease: New Drugs, Markets, and Companies. Jain PharmaBiotech Publications, Basel, Switzerland, 2010.
Jicha GA, Parisi JE, Dickson DW, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol 2006;63:674–81.
Lahiri DK, Chen D, Vivien D, et al. Role of cytokines in the gene expression of amyloid beta-protein precursor: identification of a 5′-UTR-binding nuclear factor and its implications in Alzheimer’s disease. J Alzheimers Dis 2003;5:81–90.
Levey A, Lah J, Goldstein F, et al. Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer’s disease. Clin Ther 2006;28:991–1001.
Olson L, Nordberg A, von Holst H, et al. Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer’s disease patient. J Neural Transm Park Dis Dement Sect 1992;4:79–95.
Ramirez BG, Blazquez C, Gomez del Pulgar T, et al. Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 2005;25:1904–13.
Ritchie CW, Bush AI, Mackinnon A, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting a amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 2003;60:1685–91.
Sanokawa-Akakura R, Dai H, Akakura S, et al. A novel role for the immunophilin FKBP52 in copper transport. J Biol Chem 2004;279:27845–8.
Smith AD, Smith SM, de Jager CA, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS ONE 2010;5(9):e12244; DOI: 10.1371/journal.pone.0012244.
Snitz BE, O’Meara ES, Carlson MC, et al. Ginkgo biloba for preventing cognitive decline in older adults. JAMA 2009;302:2663–70.
Tobinick E. Perispinal etanercept for neuroinflammatory disorders. Drug Discov Today 2009;14:168–77.
Tobinick EL, Gross H. Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer’s disease. BMC Neurol 2008;8:27; DOI: 10.1186/1471-2377-8-27.
Treiber C, Simons A, Strauss M, et al. Clioquinol mediates copper uptake and counteracts Cu efflux activities of the amyloid precursor protein of Alzheimer’s disease. J Biol Chem 2004;279:51958–64.
Tuszynski MH, Thal L, Pay M, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005;11:551–5.
Vega GL, Weiner MF, Lipton AM, et al. Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch Neurol 2003;60:510–5.
Weinreb O, Amit T, Bar-Am O, et al. The neuroprotective mechanism of action of the multimodal drug ladostigil. Front Biosci 2008;13:5131–7.
Wolozin B, Wang SW, Li NC, et al. Simvastatin is associated with a reduced incidence of dementia and Parkinson’s disease. BMC Med 2007;5:20.
Yao ZX, Han Z, Drieu K, et al. Ginkgo biloba extract (Egb 761) inhibits beta-amyloid production by lowering free cholesterol levels. J Nutr Biochem 2004;15:749–56.
Yogev-Falach M, Amit T, Bar-Am O, et al. Involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. FASEB J 2002;16:1674–6.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Jain, K.K. (2011). Neuroprotection in Alzheimer’s Disease. In: The Handbook of Neuroprotection. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-049-2_8
Download citation
DOI: https://doi.org/10.1007/978-1-61779-049-2_8
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61779-048-5
Online ISBN: 978-1-61779-049-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)